AssetID: 54674247
Headline: New Pill Rivals Ozempic in Weight and Sugar Control
Caption: A new daily pill for weight loss has shown strong results in a major clinical trial. Participants taking 36mg of orforglipron lost an average of 7.3kg (16lbs) in 9 months. The drug also significantly lowered blood sugar—sometimes below diabetes thresholds. Developed by Eli Lilly, the pill was tested on 559 obese patients with type 2 diabetes. Unlike injectable drugs like Ozempic, orforglipron is a once-daily pill version of a GLP-1 agonist. The company says the pill met expectations for safety, tolerability, glucose control, and weight loss.
Keywords: Eli Lilly,Ozempic,Pill,Drug,Weight loos,Orforglipron,Diabetes,Type 2 diabetes,Clinical trial,Blood sugar,Weight,Injectable,Weight management,Glucose control
PersonInImage: